Ciba
This article was originally published in The Tan Sheet
Executive Summary
Sales of its worldwide self- medication business increased 6.4% in the first half of 1994 to reach $339.2 mil. from $319.9 mil. in the first six months of 1993, Ciba reported Aug. 31. Ciba said that the self-medication division "performed particularly well in the U.S. due to the Efidac/24 cold treatment and acquired Fisons products." Ciba, which had looked at acquiring Sterling's OTC business prior to SmithKline's purchase of Sterling, is understood to be considering expanding its U.S. OTC activities